Satsuma Pharmaceuticals, Inc.
STSA · NASDAQ
3/31/2023 | 12/31/2022 | 9/30/2022 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $7 | $9 | $11 | $12 |
| G&A Expenses | $3 | $3 | $4 | $4 |
| SG&A Expenses | $3 | $3 | $4 | $4 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $11 | $12 | $15 | $16 |
| Operating Income | -$11 | -$24 | -$15 | -$16 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | $0 | $0 | $0 |
| Pre-Tax Income | -$10 | -$23 | -$15 | -$16 |
| Tax Expense | -$0 | -$1 | -$0 | -$0 |
| Net Income | -$10 | -$23 | -$15 | -$16 |
| % Margin | – | – | – | – |
| EPS | -0.3 | -0.68 | -0.47 | -0.51 |
| % Growth | 55.9% | -44.7% | 7.8% | – |
| EPS Diluted | -0.3 | -0.68 | -0.47 | -0.51 |
| Weighted Avg Shares Out | 33 | 33 | 32 | 32 |
| Weighted Avg Shares Out Dil | 33 | 33 | 32 | 32 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | -$0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $12 | $0 | $0 |
| EBITDA | -$10 | -$11 | -$15 | -$16 |
| % Margin | – | – | – | – |